{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=interferon+alpha&page=9",
    "query": {
      "intervention": "interferon alpha",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 315,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=interferon+alpha&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=interferon+alpha&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:52:26.146Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00505635",
      "title": "Biochemotherapy With Temozolomide for Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Velban",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Intron-A",
          "type": "DRUG"
        },
        {
          "name": "Thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2007-03",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505635"
    },
    {
      "nct_id": "NCT00004244",
      "title": "Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2000-03",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2013-03-21",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004244"
    },
    {
      "nct_id": "NCT00276536",
      "title": "Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Kidney Cancer",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alpha-1b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IFN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 35,
      "start_date": "2001-01",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2015-10-14",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276536"
    },
    {
      "nct_id": "NCT02452814",
      "title": "Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HCV"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-05-07",
      "completion_date": "2017-05-03",
      "has_results": false,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452814"
    },
    {
      "nct_id": "NCT00561912",
      "title": "Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Interferon Alfa-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-10",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2011-12-26",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00561912"
    },
    {
      "nct_id": "NCT00004104",
      "title": "Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "liposomal interleukin-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polyvalent melanoma vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-03-31",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004104"
    },
    {
      "nct_id": "NCT01872936",
      "title": "Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Miravirsen",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santaris Pharma A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2014-11-18",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01872936"
    },
    {
      "nct_id": "NCT01625793",
      "title": "Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Interferon-alpha",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-06",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Atlanta, Georgia",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01625793"
    },
    {
      "nct_id": "NCT00041327",
      "title": "Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "lamivudine",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AIDS Malignancy Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 19,
      "start_date": "2002-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2016-02-03",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Miami, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041327"
    },
    {
      "nct_id": "NCT05729139",
      "title": "Cemiplimab/Peg-Interferon-α in Advanced CSCC",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Advanced Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cemiplimab-Rwlc",
          "type": "DRUG"
        },
        {
          "name": "PEG-IFN alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-07",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-11-15T12:52:26.146Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05729139"
    }
  ]
}